Investors may wish to note that the Independent Director of Anika Therapeutics, Inc., Raymond Land, recently netted US$85k from selling stock, receiving an average price of US$42.60. It might not be a huge sale, but it did reduce their holding size 20%, hardly encouraging.
The Last 12 Months Of Insider Transactions At Anika Therapeutics
Notably, that recent sale by Independent Director Raymond Land was not the only time they sold Anika Therapeutics shares this year. They previously made an even bigger sale of -US$127k worth of shares at a price of US$36.77 per share. So it's clear an insider wanted to take some cash off the table, even below the current price of US$43.68. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. We note that the biggest single sale was only 37%of Raymond Land's holding.
In the last year Anika Therapeutics insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Our data suggests Anika Therapeutics insiders own 0.8% of the company, worth about US$5.0m. We consider this fairly low insider ownership.
What Might The Insider Transactions At Anika Therapeutics Tell Us?
An insider hasn't bought Anika Therapeutics stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we're not rushing to buy, to say the least. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Anika Therapeutics. In terms of investment risks, we've identified 2 warning signs with Anika Therapeutics and understanding these should be part of your investment process.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
If you decide to trade Anika Therapeutics, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.